Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

All-trans retinoic acid for refractory cancer therapy-induced thrombocytopenia: A new option beyond TPO-ras?

Linya Wang, Haitao Gao, Qiang Fu, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Feifei Tang

Blood (2025) 146 (Supplement 1): 1265.

https://doi.org/10.1182/blood-2025-1265

Published: 2025

Journal Articles

Bzip in-frame mutations might abrogate the adverse prognosis of therapy-related CEBPA-mutated AML

Guanghui Chang, Haitao Gao, Qiang Fu, Xiaosu Zhao, Yu Wang, Qian Jiang, Hao Jiang, Lanping Xu, Xiaohui Zhang, Xiaojun Huang, Feifei Tang

Blood (2025) 146 (Supplement 1): 5163.

https://doi.org/10.1182/blood-2025-5163

Published: 2025

Journal Articles

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Blood (2025) 146 (Supplement 1): 5162.

https://doi.org/10.1182/blood-2025-5162

Published: 2025

Journal Articles

Co-mutation of BCOR and BCORL1 was associated with favorable outcome in the adverse risk patients with Acute Myeloid Leukemia

Shunjie Yu, Zongru Li, Lijuan Hu, Ya-Zhen Qin, Guorui Ruan, Yazhe Wang, Hao Jiang, Feifei Tang, Jinsong JIA, Jing Wang, Qiang Fu, Xiaohui Zhang, Lanping Xu, Yu Wang, Yuqian Sun, Yueyun Lai, Hong-Xia Shi, Xiaojun Huang, Qian Jiang

Blood (2025) 146 (Supplement 1): 3400.

https://doi.org/10.1182/blood-2025-3400

Published: 2025

Journal Articles

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Zongru Li, Lu Yu, Lijuan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Qiang Fu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 4235.

https://doi.org/10.1182/blood-2024-209768

Published: 2024

Journal Articles

Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study

Wei-Bin Wu, Ya-Wen Luo, Siqi Li, Lanping Xu, Yu Wang, Xiaohui Zhang, Yuqian Sun, Feifei Tang, Xiaodong Mo, Kai-Yan Liu, Xiao-Su Zhao, Xiang-Yu Zhao, He-Bing Chen, Ying-Jun Chang, Xiaojun Huang

Blood (2024) 144 (Supplement 1): 1834.

https://doi.org/10.1182/blood-2024-207920

Published: 2024

Journal Articles

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia

Lin-Ya Wang, Feifei Tang, Xiao-Jun Huang, Hai-Tao Gao, Qiang Fu, Qian Jiang, Hao Jiang, Yu Wang, Lan-Ping Xu, Xiaohui Zhang

Blood (2024) 144 (Supplement 1): 6067.

https://doi.org/10.1182/blood-2024-202795

Published: 2024

Journal Articles

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Lu Yu, Lijuan Hu, Zongru Li, Ting Zhao, Wenbing Duan, Jing Wang, JinSong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, LanPing Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 1537.

https://doi.org/10.1182/blood-2024-207269

Published: 2024

Journal Articles

Sex Differences in Disease Characteristics and Outcome in Adults with Acute Myeloid Leukemia from China

Zongru Li, Lu Yu, Li-Juan Hu, Ting Zhao, Wenbing Duan, Jing Wang, Jinsong Jia, Jing Liu, Ya-Zhen Qin, Hao Jiang, Xiaohui Zhang, Feifei Tang, Yuqian Sun, XiaoDong Mo, Lanping Xu, Yu Wang, Xiaojun Huang, Qian Jiang

Blood (2024) 144 (Supplement 1): 6121.

https://doi.org/10.1182/blood-2024-211874

Published: 2024

Journal Articles

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia

Xiaolu Zhu, Feifei Tang, Wenjing Yu, Xiaosu Zhao, Yazhen Qin, Qian Jiang, Xiao Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 1481.

https://doi.org/10.1182/blood-2023-180002

Published: 2023

Journal Articles

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Feifei Tang, Wen-Bing Duan, Xiao-Hong Liu, Sheng-Ye Lu, Xiao-Su Zhao, Ya-Zhen Qin, Jin-Song Jia, Jing Wang, Li-Zhong Gong, Qian Jiang, Zhao Ting, Hong-Xia Shi, Ying-Jun Chang, Xiao-Jun Huang, Hao Jiang

Blood (2023) 142 (Supplement 1): 4288.

https://doi.org/10.1182/blood-2023-188657

Published: 2023

Journal Articles

Superiority of Leukemic Stem Cell-Based Minimal Residual Disease Assay to Traditional Multiparameter Flow Cytometry-Based Method for Relapse Prediction in AML Patients: A Prospective Study with Randomized Training and Validation Sets

Siqi Li, Lan-Ping Xu, Yu Wang, Xiaohui Zhang, Huan Chen, Yu-Hong Chen, Fengrong Wang, Wei Han, Yuqian Sun, Chenhua Yan, Meng Lyu, Feifei Tang, Xiao-Dong Mo, Kai-Yan Liu, Yingjun Chang, Xiao Jun Huang

Blood (2021) 138 (Supplement 1): 517.

https://doi.org/10.1182/blood-2021-150011

Published: 2021

Journal Articles

Risk Factors and Different Therapeutic Patterns of Late-Onset Hemorrhagic Cystitis after Haploidentical Allogeneic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 3261.

https://doi.org/10.1182/blood-2019-126230

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

All-trans retinoic acid for refractory cancer therapy-induced thrombocytopenia: A new option beyond TPO-ras?

Bzip in-frame mutations might abrogate the adverse prognosis of therapy-related CEBPA-mutated AML

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction?

Co-mutation of BCOR and BCORL1 was associated with favorable outcome in the adverse risk patients with Acute Myeloid Leukemia

The Bone Marrow Blasts on Day 14 during the Azacitidine Plus Venetoclax Regimen As the Induction Therapy Can Predict the Outcome in Unfit Patients with Newly Diagnosed Acute Myeloid Leukemia

Myelodysplastic Syndrome Stem Cells Evaluated By Multiparameter Flow Cytometry Are Associated with Posttreatment Relapse: A Prospective Study

Clinical and Molecular Predictors of Response and Survival Following Venetoclax Plus Hypomethylating Agents in Relapsed/Refractory Acute Myeloid Leukemia

Genetic Abnormalities Associated with Outcomes in Unfit Patients with Acute Myeloid Leukemia Receiving Less Intensive Therapy in the Real World

Sex Differences in Disease Characteristics and Outcome in Adults with Acute Myeloid Leukemia from China

Cytoreductive Chemotherapy in Induction Therapy Plays a Key Role in the Prognosis of Patients with Low-Risk Acute Promyelocytic Leukemia

A Completely Oral Regimen Including Oral Etoposide As Cytoreductive Chemotherapy Combined with All Trans Retinoic Acid and Oral Arsenic for Induction Therapy in Patients with High-Risk APL：Comparable to Intravenous Cytoreductive Therapy

Superiority of Leukemic Stem Cell-Based Minimal Residual Disease Assay to Traditional Multiparameter Flow Cytometry-Based Method for Relapse Prediction in AML Patients: A Prospective Study with Randomized Training and Validation Sets

Risk Factors and Different Therapeutic Patterns of Late-Onset Hemorrhagic Cystitis after Haploidentical Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only